The European Commission (EC) approved Jardiance (empagliflozin) for the treatment of adults with chronic kidney disease (CKD), Boehringer Ingelheim and Eli Lilly and Company have announced. The approval has the potential to advance the standard of care for more than 47 million people in the EU living with CKD and help relieve burden on healthcare systems by reducing the risk […]
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Mircera (methoxypolyethylene glycolepoetin beta). The marketing authorisation holder for this medicinal product is Roche Registration GmbH. The CHMP adopted an extension to an existing indication for use in paediatric patients. For information, the […]
This randomized trial recently published in the American Journal of Kidney Diseases (AJKD) found that a 12- month program of in-center aerobic and resistance exercise program improved physical functioning among adults 55 years and older with CKD stages G3b-4 and a high level of medical comorbidities. Among adults ≥55 years with CKD stages G3b-4 and with a high level of co-morbidity, a […]
The European Commission has granted marketing authorization in the European Union (EU) for finerenone under the brand name Kerendia from Bayer HealthCare. Kerendia (10 mg or 20 mg), a non-steroidal, selective mineralocorticoid receptor antagonist, is indicated for the treatment of chronic kidney disease (stage 3 and 4 with albuminuria) associated with type 2 diabetes in adults. “Even when blood glucose […]
A commonly available pesticide has been associated with an increased risk of chronic kidney disease (CKD) in a University of Queensland study. Researchers analysed links between pesticide exposure and the risk of kidney dysfunction in 41,847 people, using data from the USA National Health and Nutrition Examination Survey (NHANES). School of Public Health Associate Professor, Nicholas Osborne said the study found people […]
Recent Comments